Xeris rises on 2026 revenue guidance, Q4 top-line beat

2026-03-02 12:08:38 ET

More on Xeris Biopharma

• Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
• Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
• Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
• Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
• Xeris Biopharma expects full-year 2025 revenue above estimates

Read the full article on Seeking Alpha

For further details see: